Using Ultrasound to Predict the Results of Draining Pleural Effusions
Launched by UNIVERSITY OF OXFORD · Oct 25, 2013
Trial Information
Current as of June 28, 2025
Terminated
Keywords
ClinConnect Summary
Study-specific interventions will be the monitoring of intrapleural pressure using an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device) and thoracic ultrasonography. Both of these are considered non-invasive and low-risk to the study participants.
As part of their standard usual clinical care, participants will undergo a diagnostic and/or therapeutic pleural intervention in the form of thoracocentesis or pleural aspiration; intercostal chest drain insertion; and/or talc pleurodesis. All of these procedures are invasive and associated with potential com...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The participant is willing and able to give informed consent for participation in the study.
- • Adult male or female, aged 18 years or above.
- • Diagnosed with a symptomatic pleural effusion requiring either diagnostic and/or therapeutic pleural aspiration or drainage.
- • Expectation by the clinician responsible for assessing the patient that more than 500mL of pleural fluid will be drained on this particular occasion.
- Exclusion Criteria:
- • Age less than 18 years
- • Inability to provide informed consent
- • Evidence of significant septation or loculation within the pleural effusion as determined by the clinician responsible for assessing the patient.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Patients applied
Trial Officials
Najib Rahman, DPhil, MSc, MRCP
Study Chair
University of Oxford & Oxford University Hospitals NHS Trust
John Corcoran, MD
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials